The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is adjuvant chemotherapy after secondary debulking surgery for recurrent ovarian cancer necessary?
Munetaka Takekuma
No relevant relationships to disclose
Keita Mori
No relevant relationships to disclose
Satomi Komeda
No relevant relationships to disclose
Shiho Kuji
No relevant relationships to disclose
Aki Tanaka
No relevant relationships to disclose
Nobutaka Takahashi
No relevant relationships to disclose
Masakazu Abe
No relevant relationships to disclose
Yasuyuki Hirashima
No relevant relationships to disclose